Most of us shrug off little memory slips as part of getting older. You forget a name in a meeting or stand in the kitchen wondering why you walked in. A new line of research suggests something more specific may be going on inside aging brain cells.
Scientists at the University of New Mexico have zeroed in on a single enzyme, called OTULIN, that appears to act like a master switch for both the toxic tau protein and broader brain aging programs.
When they dialed this protein down in lab grown human neurons, tau all but vanished and the cells stayed healthy. The work points to a possible way to tackle brain aging at its source instead of only cleaning up the damage that shows up years later.
Tau, brain aging, and why this matters
Tau has been on scientists’ radar for a long time. In healthy neurons it helps stabilize tiny internal tracks that give the cells structure and let signals move efficiently.
In Alzheimer’s disease and more than twenty related conditions, tau becomes chemically altered and starts clumping inside neurons. These tangles are one of the classic hallmarks seen in patient brain tissue.
Over the past decade, treatments aimed at another protein called amyloid beta have had only modest effects in people already living with dementia. That has nudged many labs toward tau as a more promising target. The New Mexico team had already been working on a vaccine that trains the immune system to clear harmful forms of tau.
At the end of the day, the question is simple. If tau is such a central troublemaker, can you safely turn it off without wrecking the neuron that depends on it.
Flipping OTULIN inside human neurons
The new study focused on OTULIN, a protein better known for helping control inflammation and a cellular cleaning process called autophagy. OTULIN normally removes a specific kind of molecular tag from other proteins.
The team wondered what would happen if they interfered with that activity in nerve cells that carry a heavy load of tau.
They used two human cell models. One came from induced stem cell neurons derived from a person with late onset sporadic Alzheimer’s disease.
The other was a widely-used human neuroblastoma cell line. In both systems, the scientists either knocked out the OTULIN gene using CRISPR Cas9 gene editing or treated cells with a custom designed small molecule that blocks OTULIN.
The result surprised even the authors. When OTULIN was fully disabled, tau did not simply get chewed up more quickly. Instead, the messenger RNA that tells the cell how to make tau largely disappeared. In some neuron models, both total tau and its pathological forms dropped to almost undetectable levels.
Yet the neurons did not fall apart. Lead author Karthikeyan Tangavelou put it simply, saying that “pathological tau is the main player for both brain aging and neurodegenerative disease” and that “neurons can survive without tau.”
For anyone worrying about a relative’s fading memory, that combination sounds almost too good to be true. Cells with no tau and no obvious stress.
A possible master regulator of brain aging
Once OTULIN was shut down, the team did not stop at tau. They ran large-scale RNA sequencing to see what happened to the full set of genetic messages inside those neurons. The answer was sweeping.
More than thirteen thousand genes changed their activity, and tens of thousands of RNA transcripts shifted up or down. Many of the altered messages are tied to inflammation and to systems that govern how long RNA molecules stick around before being degraded.
That pattern fits with what happens in the aging brain. Over time, neurons lose their balance between making new proteins and clearing out damaged ones.
By the researchers’ own account, OTULIN seems to sit near the top of this traffic system, affecting protein quality control, cell survival, and now RNA metabolism itself. One reason they describe it as a “master regulator” of brain aging is that a single change in OTULIN triggered a kind of domino effect across thousands of genes.
In practical terms, that means OTULIN is not just a tau switch. It looks more like a control knob for how an aging neuron manages stress and inflammation over many years.
Hope, but also some careful caveats
The story is not as simple as turning OTULIN off and calling it a day. The same experiments that wiped out tau also showed how risky a complete shutdown could be.
With OTULIN fully deleted, the gene expression changes were so widespread that they might prove dangerous in a real human brain, where billions of cells need to stay in sync.
To a large extent, the safer option seems to be partial inhibition. In the study, an experimental compound known as UC495 reduced harmful phosphorylated tau in Alzheimer’s neurons without erasing all tau or obvious signs of toxicity. That hints at a narrow window where OTULIN activity could be tuned rather than silenced.
There is another layer of complexity. Neurons share the brain with astrocytes, microglia, oligodendrocytes, and the endothelial cells that line blood vessels. Early work suggests that OTULIN might behave differently in some of these cell types.
If the protein is missing in microglia, for instance, it could spark unwanted inflammation even while it helps neurons. The team is now testing OTULIN’s role across this wider cast of cells and in animal models.
For now, no one is getting an OTULIN-based drug from the pharmacy. This is bench science, done in dishes of human cells, not in people juggling work, family, and the usual brain fog after a bad night’s sleep. Yet it shifts the conversation about brain aging.
Instead of only scrubbing away protein clumps, scientists may be able to rewrite some of the instructions that make those clumps in the first place.
The study was published in Genomic Psychiatry.
